Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

(2020) Adam J Schoenfeld et al.   CLINICAL CANCER RESEARCH

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Kazuhiko Nakagawa et al.   LANCET ONCOLOGY

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

(2018) Jacqulyne P. Robichaux et al.   NATURE MEDICINE

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

(2017) Monique B. Nilsson et al.   Science Translational Medicine

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

(2015) M. B. Nilsson et al.   CLINICAL CANCER RESEARCH

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

(2014) Takashi Seto et al.   LANCET ONCOLOGY

ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2013) Bruce E. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma

(2011) Tina Cascone et al.   JOURNAL OF CLINICAL INVESTIGATION

Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors

(2010) M B Nilsson et al.   ONCOGENE

Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells

(2010) L Xu et al.   ONCOGENE

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

(2009) G. N. Naumov et al.   CLINICAL CANCER RESEARCH

Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer

(2009) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Hypoxic Regulation of Metastasis via Hypoxia-Inducible Factors

(2008) Marc Vooijs et al.   CURRENT MOLECULAR MEDICINE